Who is sponsoring NCT00720902?

NCT00720902 is sponsored by Columbia University.

What condition does NCT00720902 study?

NCT00720902 studies Growth Hormone Deficiency.

What drugs are being tested in NCT00720902?

Interventions: Blood draws, growth hormone releasing hormone (GHRH) & arginine, Carotid ultrasound, MRI, Endothelial cell biopsy.

What is the status of NCT00720902?

NCT00720902 is currently TERMINATED.

Last reviewed 2022-10-24 · How we verify

Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas

NCT00720902 Phase 4 TERMINATED Results posted

This protocol will assess the cardiovascular risk associated with growth hormone deficiency in adults. We will use multiple modalities to assess risk for heart attacks or strokes including blood work, ultrasound, MRI and endothelial cell biopsies in both patients who are growth hormone deficient and in patients with normal growth hormone secretion. We hypothesize that adults with growth hormone deficiency will have results suggestive of an increased risk for cardiovascular disease.

Details

Lead sponsor	Columbia University
Phase	Phase 4
Status	TERMINATED
Enrolment	7
Start date	2007-02
Completion	2011-05

Conditions

Growth Hormone Deficiency

Interventions

Blood draws
growth hormone releasing hormone (GHRH) & arginine
Carotid ultrasound
MRI
Endothelial cell biopsy

Primary outcomes

C-reactive Protein (CRP) Levels — Day 1
C-reactive protein (CRP) levels in GH sufficient and GH deficient participants
Homocysteine Level — Day 1
Homocytsteine levels in GH sufficient and GH deficient participants
Total Cholesterol Level — Day 1
Total cholesterol levels in GH sufficient and GH deficient participants

Countries

United States